Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Regenerative medicine
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 230517
The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patientâ€™s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patientâ€™s heart with autologous muscle cells, or cells from a patientâ€™s body, for the purpose of improving cardiac function in chronic heart failure patients.
IPSCIO Record ID: 3444
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
IPSCIO Record ID: 240469
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
IPSCIO Record ID: 28172
The Licensee may assigning or subcontract the rights with permission from the Licensor.
2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.
And the related Patents and Patent Applications;
06/592,871 Stem Cells and treatment of Vascular Tissue
06/680,775 Treating Cardiovascular Tissue
06/832,845 Methods and Materials for providing Cardiac Cells
PCT/US2005/026800 Treating Cardiovascular Tissue
PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue
PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue
PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells
3. Paragraph 2.02 is replaced with the following;
Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.
The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.
IPSCIO Record ID: 28946
Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.
BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.
BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heartâ€™s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.
IPSCIO Record ID: 369277
Licensor hereby grants to Licensee and Licensee accepts from Licensor, a non-exclusive, worldwide, right and license, including the right to sublicense, to the Know-How.
Licensor hereby grants to Licensee and Licensee accepts from Licensor for the Option Period (in each case) a non-transferable (except as specifically stated in Agreement), exclusive option to negotiate in good faith for a royalty-bearing, worldwide, exclusive license, including the right to sublicense, to practice all the rights under the New Development Patents in the Licensed Field only (the Option).
6,673,339 – Prosthetic kidney and its use for treating kidney disease
6,576,019 – Bladder reconstruction
6,514,292 – Corporal tissue penile reconstruction
The primary focus of the research will be on creating â€œneo-organsâ€ and tissues. Neo-organs and tissues are derived from a patientâ€™s own cells that are grown on a scaffold or model that is bioresorbable, or can be absorbed by the body. These neo-organs become functional replacements after being implanted in the patientâ€™s body. Since they come from a patientâ€™s own cells (autologous cells) there is virtually no risk of rejection from the bodyâ€™s immune system.
In tissue engineering, neo-organ is a final structure of procedure based on transplantation of constructs consisting of endogenous stem/progenitor cells grown ex vivo within predesigned matrix scaffolds. The scaffold eventually is resorbed, leaving transplanted cells and the stroma that they produce in the body.
Licensed Field means human and animal organs, tissues and tissue-engineered and regenerative medicine products directed to their functions in the following areas (i) Genitourinary Tissue, (ii) Kidney Tissue, (iii) Cardiovascular Tissue, (iv) Nervous Tissue, and (v) Trachea Tissue. Each of Genitourinary Tissue, Kidney Tissue, Cardiovascular Tissue and Nervous Tissue is a Subfield.
Genitourinary Tissue means the reproductive system and the urinary system, including the male and female internal and external genitalia as well as all organs concerned in the formation and voidance of urine, but excluding Kidney Tissue. For the removal of doubt, Genitourinary Tissue is not to be considered Cardiovascular Tissue merely because it contains components of Cardiovascular Tissue.
Kidney Tissue means the kidney.
Cardiovascular Tissue means arteries, arterial tissue, veins and venous tissue. Cardiovascular Tissue does not include cardiac muscle tissue or heart valves.
Nervous Tissue means the (i) central nervous system, (ii) peripheral nervous system, and (iii) functional subcomponents and subunits of (i) and (ii) above. For the removal of doubt, a tissue or organ is not considered Nervous Tissue merely because it contains components of Nervous Tissue.
Trachea Tissue means the trachea and functional subcomponents and subunits thereof. Trachea Tissue does not include the bronchus and larynx.
IPSCIO Record ID: 4005
IPSCIO Record ID: 353931
Sub-licensor is engaged in the research, development, manufacture and marketing of perfusion decellularization and recellularization technology and the products that are created utilizing such technology.
Decellularization. The anatomical structure of organs is highly complex and enormously challenging to reproduce synthetically. We utilize porcine organs as the scaffold for creating human organs because significant anatomical and vascular similarities exist between the two speciesâ€™ scaffolding. Using our proprietary perfusion decellularization process we remove the porcine cells from harvested porcine organs leaving behind a scaffold of extracellular matrix (â€œECMâ€) that retains the architecture, mechanical properties, and vascular network of the original organ structure. Porcine ECM is estimated to be over 93% homologous to human ECM which significantly reduces potential for antibody formation and adverse reaction. In addition, we have generated human clinical data demonstrating the safety of our decellularized porcine liver scaffold in clinical trials of two products we previously developed, commercialized and spun out, MiromeshÂ® and MirodermÂ®.
Recellularization. Recellularization is the process of growing new functional organs starting with the ECM that remains after the decellularization process is completed. We currently use living human cells harvested from organ donors to re-seed the ECM, and in the future intend to develop new techniques using patient-derived stem cells. Living human cells are adaptive, and when introduced into the decellularized ECM display unique regenerative, plasticity, and adhesion properties. The process of recellularization occurs in a bioreactor where media and living human cells are perfused into the ECM in the appropriate sequence in order to facilitate cellular regeneration and organ functionality.
IPSCIO Record ID: 213335